High pathological responses in borderline resectable NSCLC patients after induction with dual immunotherapy and concurrent chemoradiotherapy Presented ByDr Idris Bahce, Amsterdam UMC, the Netherlands TrialPhase 2, INCREASE ConferenceESMO 2022 16 November, 2022 18:05